Standards; Enzyme Activators and Inhibitors; Pharmaceutical/API Drug Impurities/Metabolites;
应用
Desamino Hydroxy Lenvatinib serves as a reagent for the synthesis of urea derivatives containing nitrogenous aromatic ring compounds that functions as angiogenesis inhibitors for treatment of diseases. It is also a derivative compound of Lenvatinib (L329400) that serves as orally active inhibitor of multiple receptor tyrosine kinases including VEGF, FGF and SCF receptors.
参考文献
Funahashi, Y., et al.: PCT Int. Appl. (2002), WO 2002032872 A1 20020425; Matsui, J., et al.: Clin. Cancer Res., 14, 5459 (2008); Gild, M., et al.: Nature Rev. Endocrinol., 7, 617 (2011)
沪ICP备17019645号
400-821-0725
